Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine in Metastatic Colorectal Cancer (MKK3 Inhibition)
2024-519459-27-00Phase 2Authorised
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine in metastatic colon cancer (mCRC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Objective response rate (ORR). Planned start May 2025; status: authorised.
02
Drugs
vinorelbine
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-519459-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519459-27-00.